Skip to content
value.today

New Health Sciences, Inc.

Formerly New Health Systems Inc

Total raised
$135 M
9 rounds on record
Latest round
$20 M
Jul 2025
First round on record
Jul 2011
Today
Private
No later event on record

Funding rounds

9 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of New Health Sciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$20 MNo. 9$10 to $50 million

New Health Sciences, Inc.: Raise no. 9, Jul 2025

Investors in this round

29 investors had bought by the notice of Aug 5, 2025: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $24 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$41,250
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, and Member of the Board of Directors
  • Daan M. Kok · Executive Officer · Head of Business Development and Strategy
  • Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer, and Corporate Secretary
  • Jill J. Buckley · Executive Officer · Vice President of Human Resources
  • Laura J. Daniels · Executive Officer · Vice President of Product Development
  • Laurel J. Omert · Executive Officer · Chief Medical Officer
  • Robert J. Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Geoffrey M. Crouse · Director
  • Ismail M. Kola · Director
  • Joseph M. Grogan · Director
  • Paul M. Ness · Director
  • Peter A. Testa · Director
  • Philip M. Pead · Director
  • Stephen A. Eckert · Director · Chairman of the Board of Directors
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Octavian AG · Zurich, SwitzerlandSold in no state named, and outside the US

Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Aug 5, 2025. Read the notice at the SEC.

equitySEC
Nov 2024$22 MNo. 8$10 to $50 million

New Health Sciences, Inc.: Raise no. 8, Nov 2024

Investors in this round

51 investors had bought by the notice of Jul 31, 2025: 51 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$27,188
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, and Member of the Board of Directors
  • Daan M. Kok · Executive Officer · Head of Business Development and Strategy
  • Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer, and Corporate Secretary
  • Jill J. Buckley · Executive Officer · Vice President of Human Resources
  • Laura J. Daniels · Executive Officer · Vice President of Product Development
  • Laurel J. Omert · Executive Officer · Chief Medical Officer
  • Robert J. Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Geoffrey M. Crouse · Director
  • Ismail M. Kola · Director
  • Joseph M. Grogan · Director
  • Paul M. Ness · Director
  • Peter A. Testa · Director
  • Philip M. Pead · Director
  • Stephen A. Eckert · Director · Chairman of the Board of Directors
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Octavian AG · Zurich, SwitzerlandSold in no state named, and outside the US

Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Jul 31, 2025. Read the notice at the SEC.

equitySEC
Dec 2023$5 MNo. 7$2 to $10 million

New Health Sciences, Inc.: Raise no. 7, Dec 2023

Investors in this round

10 investors had bought by the notice of Jan 8, 2024: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors
  • Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA
  • Eric J. Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary
  • Jill J. Buckley · Executive Officer · Vice President of Human Resources
  • Laura J. Daniels · Executive Officer · Vice President of Product Development
  • Laurel J. Omert · Executive Officer · Chief Medical Officer
  • Robert J. Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Ismail M. Kola · Director
  • Michael David Testa · Director
  • Paul M. Ness · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director · Chairman of the Board of Directors
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric J. Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Jan 8, 2024. Read the notice at the SEC.

equitySEC
Jun 2023$11 MNo. 6$10 to $50 million

New Health Sciences, Inc.: Raise no. 6, Jun 2023

Investors in this round

20 investors had bought by the notice of Nov 8, 2023: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$400,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Dunham · Executive Officer, Director · President, Chief Executive Officer, Chief Technology Officer and Member of the Board of Directors
  • Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA
  • Eric Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary
  • Jill Buckley · Executive Officer · Vice President of Human Resources
  • Laura Daniels · Executive Officer · Vice President of Product Development
  • Laurel Omert · Executive Officer · Chief Medical Officer
  • Robert Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Ismail M. Kola · Director
  • Michael David Testa · Director
  • Paul M. Ness · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director · Chairman of the Board of Directors
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Sonenshine & Company LLC (CRD 104357) · New York, New YorkSold in AL, CA, CO, CT, DE, FL, GA, IL, MA, MD, ME, MN, MO, NH, NV, NY, OH, PA, TX, VA, WA, and outside the US

Remarks in the notice

  • On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”

Signed by Eric Newman, Vice President Chief Financial Officer & Corporate Secretary. Source: SEC Form D, newest notice filed Nov 8, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2022$13 MNo. 5$10 to $50 million

New Health Sciences, Inc.: Raise no. 5, Jul 2022

Investors in this round

38 investors had bought by the notice of Feb 7, 2023: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $15 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,125,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex A. Marichal · Executive Officer · Vice President of Marketing
  • Andrew A. Dunham · Executive Officer · Vice President and Chief Technology Officer
  • Daan M. Kok · Executive Officer · Executive Vice President & General Manager, EMEA
  • Eric A. Newman · Executive Officer · Vice President, Chief Financial Officer and Corporate Secretary
  • Jill A. Buckley · Executive Officer · Vice President of Human Resources
  • Kimberly M. Dorsch · Executive Officer · Vice President, Clinical Affairs
  • Laura A. Daniels · Executive Officer · Vice President of Product Development
  • Laurel A. Omert · Executive Officer · Chief Medical Officer
  • Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and Member of the Board of Directors
  • Robert A. Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Guy A. Cogan · Director
  • Ismail M. Kola · Director
  • Michael David Testa · Director
  • Paul M. Ness · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Sonenshine & Company LLC (CRD 104357) · New York, New YorkSold in AL, CA, CT, DE, GA, IL, MA, ME, NH, NY, OH, PA, TX, VA, and outside the US

Remarks in the notice

  • On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”

Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Feb 7, 2023. Read the notice at the SEC.

equitySEC
Aug 2019$40 MNo. 4$10 to $50 million

New Health Sciences, Inc.: Raise no. 4, Aug 2019

Investors in this round

39 investors had bought by the notice of Oct 15, 2021: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $59 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,125,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex Patrick Marichal · Executive Officer · Vice President of Marketing
  • Andrew Patrick Dunham · Executive Officer · Vice President and Chief Scientific Officer
  • Eric Patrick Newman · Executive Officer · Vice President and Chief Financial Officer
  • Jill Patrick Buckley · Executive Officer · Vice President of Human Resources
  • Laura Patrick Daniels · Executive Officer · Vice President of Product Development
  • Laurel Patrick Omert · Executive Officer · Chief Medical Officer
  • Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors
  • Robert Patrick Haime · Executive Officer · Vice President of Commercial Operations
  • Eduardo Patrick Avayu · Director
  • Guy A. Cogan · Director
  • Michael David Testa · Director
  • Paul M. Ness · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director
  • William Patrick O'Neill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Sonenshine & Company LLC (CRD 104357) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Sonenshine & Co. is entitled to certain finders fees for certain investors.”

Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D and 2 amendments, newest notice filed Oct 15, 2021. Read the notice at the SEC.

equitySEC
Feb 2018$9 MNo. 3$2 to $10 million

New Health Sciences, Inc.: Raise no. 3, Feb 2018

Investors in this round

6 investors had bought by the notice of Oct 26, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $16 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eric David Newman · Executive Officer · Vice President and Chief Financial Officer
  • Joseph David Barrett · Executive Officer · General Counsel and Secretary
  • Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors
  • David A. Herman · Director
  • Guy A. Cogan · Director
  • Michael David Testa · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin A. Cannon, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 26, 2018. Read the notice at the SEC.

debt, optionsSEC
Oct 2017$3 MNo. 2$2 to $10 million

New Health Sciences, Inc.: Raise no. 2, Oct 2017

Investors in this round

6 investors had bought by the notice of Dec 19, 2017: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph David Barrett · Executive Officer · General Counsel and Secretary
  • Lynn David Mallett · Executive Officer · Vice President and Chief Financial Officer
  • Martin A. Cannon · Executive Officer, Director · President, Chief Executive Officer and member of the Board of Directors
  • David A. Herman · Director
  • Guy A. Cogan · Director
  • Michael David Testa · Director
  • Richard A. Perle · Director
  • Stephen A. Eckert · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin A. Cannon, President, Chief Executive Officer and Director. Source: SEC Form D, newest notice filed Dec 19, 2017. Read the notice at the SEC.

equitySEC
Jul 2011$12 MNo. 1$10 to $50 million

New Health Sciences, Inc.: Raise no. 1, Jul 2011

Investors in this round

3 investors had bought by the notice of Dec 16, 2013: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $18 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Martin A. Cannon · Executive Officer, Director · Member of Board of Directors, President and Chief Executive Officer
  • Michael A. Bavonese · Executive Officer · Director of Finance and Administration and Corporate Secretary
  • David A. Herman · Director
  • David A. Testa · Director
  • Guy A. Cogan · Director
  • Richard A. Perle · Director
  • Steve A. Eckert · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Martin A. Cannon, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 16, 2013. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • New Health Sciences, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).

    SEC Form D · Aug 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2025

That is all the official record says: New Health Sciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of New Health Sciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 9 rounds above had up to 51 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by New Health Sciences, Inc.
NameRoleNamed in
Andrew DunhamPresident, Chief Executive Officer, and Member of the Board of DirectorsAug 2025
Daan M. KokHead of Business Development and StrategyAug 2025
Eric J. NewmanVice President, Chief Financial Officer, and Corporate SecretaryAug 2025
Jill J. BuckleyVice President of Human ResourcesAug 2025
Laura J. DanielsVice President of Product DevelopmentAug 2025
Laurel J. OmertChief Medical OfficerAug 2025
Robert J. HaimeVice President of Commercial OperationsAug 2025
Eric NewmanVice President, Chief Financial Officer and Corporate SecretaryNov 2023
Jill BuckleyVice President of Human ResourcesNov 2023
Laura DanielsVice President of Product DevelopmentNov 2023
Laurel OmertChief Medical OfficerNov 2023
Robert HaimeVice President of Commercial OperationsNov 2023
Alex A. MarichalVice President of MarketingFeb 2023
Andrew A. DunhamVice President and Chief Technology OfficerFeb 2023
Eric A. NewmanVice President, Chief Financial Officer and Corporate SecretaryFeb 2023
Jill A. BuckleyVice President of Human ResourcesFeb 2023
Kimberly M. DorschVice President, Clinical AffairsFeb 2023
Laura A. DanielsVice President of Product DevelopmentFeb 2023
Laurel A. OmertChief Medical OfficerFeb 2023
Martin A. CannonPresident, Chief Executive Officer and Member of the Board of DirectorsFeb 2023
Robert A. HaimeVice President of Commercial OperationsFeb 2023
Alex Patrick MarichalVice President of MarketingOct 2021
Andrew Patrick DunhamVice President and Chief Scientific OfficerOct 2021
Eric Patrick NewmanVice President and Chief Financial OfficerOct 2021
Jill Patrick BuckleyVice President of Human ResourcesOct 2021
Laura Patrick DanielsVice President of Product DevelopmentOct 2021
Laurel Patrick OmertChief Medical OfficerOct 2021
Robert Patrick HaimeVice President of Commercial OperationsOct 2021
Alex B. MarichalVice President of MarketingOct 2019
Andrew B. DunhamVice President and Chief Scientific OfficerOct 2019
Eric B. NewmanVice President and Chief Financial officerOct 2019
Joseph B. BarrettVice President, General Counsel and Corporate SecretaryOct 2019
Laura B. DanielsVice President of Product DevelopmentOct 2019
Robert B. HaimeVice President of Commercial OperationsOct 2019
Eric David NewmanVice President and Chief Financial OfficerOct 2018
Joseph David BarrettGeneral Counsel and SecretaryOct 2018
Lynn David MallettVice President and Chief Financial OfficerFeb 2018
Michael A. BavoneseDirector of Finance and Administration and Corporate SecretaryDec 2013
Andrew DunhamPresident, Chief Executive Officer, and Member of the Board of DirectorsAug 2025
Eduardo Patrick AvayuDirectorAug 2025